May 18, 2020
Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19
Mar 13, 2020
Neuroprotection Market Insights 2018-2028 with Profiles of 140 Companies & 126 Collaborations
Feb 06, 2020
NeuroSense Therapeutics Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS) Drug, and Announces Initiation of Two Clinical Studies in ALS
Jan 24, 2020
Clene Nanomedicine Announces Formal Acceptance of CNM-Au8 for HEALEY ALS Platform Trial as Center Receives FDA Approval to Proceed
Jan 21, 2020
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
Dec 03, 2019
Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson's Disease with the Nanocatalytic Therapeutic, CNM-Au8
Sep 23, 2019
4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes
Sep 18, 2019
Clene Nanomedicine, Inc. Announces Selection of CNM-Au8 for the Harvard Led HEALEY ALS Platform Trial, a Clinical Trial for Amyotrophic Lateral Sclerosis
Jul 11, 2019
Global Neuroprotection Drugs Market is Expected to Reach US$ 33,481.7 Million by 2027, Growing at an Estimated CAGR of 1.56% Over the Forecast Period, Says Absolute Markets Insights
May 20, 2019
Neuroprotection Methods, Drugs, Markets and Competitive Landscape, 2018-2019 & 2019-2023 & 2028 with Investigation of 500+ Products
May 13, 2019
4D Announces Participation in Neuro4D Conference, Frankfurt, Germany
May 07, 2019
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
Mar 04, 2019
Mercaptor Discoveries CEO to Speak at 9th Annual Traumatic Brain Injury Conference in Washington D.C. May 16, 2019
Feb 27, 2019
Neuroprotection Methods, Drugs, Markets and Companies Report 2019: Projections to 2023 & 2028 with Profiles of 140 Companies & 123 Collaborations
Oct 12, 2018
Mercaptor Discoveries Announces Positive Preclinical Proof of Concept (POC) in NIH-Funded Studies
Oct 03, 2018
Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
Aug 06, 2018
Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Jul 18, 2018
Global Neuroprotection Drugs, Markets and Companies Research Report 2018
Jul 16, 2018
Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation